All posts by imreal

New Moms Not Receiving Adequate Education and Resources to Prepare Them for the First Six Weeks Postpartum


Aeroflow survey results highlight the challenges faced by new moms during the first six weeks postpartum.

“The weeks following birth are a very nerve-wracking and uncertain time for new moms, which is why they need to feel fully equipped with what to expect during their recovery and how to care for their baby,” said Dr. Jessica Madden, Medical Director of Aeroflow Breastpumps.

Aeroflow Healthcare today announced the results of a proprietary survey designed to highlight the experiences and struggles faced by new moms during the first six weeks postpartum, also known as the first 42 days. The third party-administered survey polled 394 women living in the United States with children between the ages 0-1 and was completed over a span of three days in March 2020. To download the full survey results, please click here.

Notable survey results include:

  • Almost all new moms (90%) believe educating mothers about what to expect/resources available during the first six weeks postpartum can and should be improved
  • An overwhelming majority of new moms (76%) were not given information or guidance regarding any products/medical devices that may help with recovery
  • The top things new moms struggled with most in the first six weeks postpartum include breastfeeding (66%), followed by postpartum depression/anxiety (48%) and social support isolation (39%)
  • One-in-four new moms (25%) report not feeling like they had access to the necessary care to address any/all of the above issues
  • Nearly three-in-five new moms (59%) felt they needed assistance to breastfeed comfortably and successfully
  • The majority of new moms (66%) report the postpartum period was more difficult than they thought it would be, which not surprisingly resulted in more than half (56%) having family/friends stay with them to help out—especially for the 25% of new moms that had to go back to work within the first six weeks after giving birth
  • Half of moms (50%) report not feeling prepared in what to expect and how to care for their body the first six weeks postpartum
  • Nearly one-in-five (19%) new moms report not being provided guidance regarding symptoms that may indicate a health concern after delivery, and when to raise these concerns to a doctor

These survey results highlight the profound hardships new moms experience when navigating the first six weeks postpartum, with many not receiving the necessary education and resources to aid in recovery and caring for a newborn. With women’s bodies undergoing drastic changes throughout and after pregnancy, new moms are experiencing physical symptoms including breast engorgement and pain (70%), soreness/pain in the vaginal and rectal areas (64%) and abdominal/uterine cramping (63%) while trying to figure out how to breastfeed successfully and properly care for a newborn.

New moms need all the support and information possible from their doctors and midwives, as almost half (48%) reported primarily feeling stressed and overwhelmed during this time. For example, a new mom’s first postpartum check-up typically takes place following the first six weeks after giving birth, but nearly two-in-five (38%) saw a healthcare provider within the first two weeks. While some of these women certainly may have required medical advice/attention, this shows there is a lot of uncertainty around what to expect and how to care for themselves and their baby during this time. As a result, many new moms are leaning on friends and family (64%) as opposed to their OB or midwife (46%) to gather information on what to expect during the postpartum period.

“The weeks following birth are a very nerve-wracking and uncertain time for new moms, which is why they need to feel fully equipped with what to expect during their recovery and how to care for their baby,” said Dr. Jessica Madden, Medical Director of Aeroflow Breastpumps. “Before moms leave the hospital with their newborns, it’s imperative that they feel confident in knowing the symptoms they will experience as their body recovers, when severity of symptoms indicate a more serious issue and the resources available to them to help with the process—especially when it comes to medical devices that will aid in healing.”

“We hope this study raises awareness about the need to improve postpartum education through all stages of a pregnancy and shows new moms all over the country that they are not alone in the challenges they face. Women need all the support possible to help them through this six-week period, so it’s important that they are not in the dark about where to turn to alleviate pain and discomfort as their bodies recover,” said Jennifer Jordan, Director of Mom and Baby at Aeroflow Healthcare. “Aeroflow proudly supports all new moms throughout their motherhood journey and remains committed to providing them with the highest quality tools, resources and medical devices to make the transition as smooth as possible.”

About Aeroflow Healthcare

Aeroflow Healthcare was founded in Asheville, NC in 2001 as a home oxygen provider, and has since grown to become a nationwide provider of durable medical equipment. In 2017, Aeroflow was also awarded the HME Excellence Award for Best Home Medical Equipment Provider and has been recognized as a business offering top-notch benefits to employees with the Great Place to Work Award. Aeroflow is an accredited Medicare and Medicaid provider and accepts most commercial insurance. To learn more about Aeroflow Healthcare and getting medical equipment through insurance, visit http://www.aeroflowinc.com.

Media Inquiries

Samantha Breccia

FischTank PR

Email: samantha@fischtankpr.com

Aeroflow Contact

Carly Fleming

Marketing Manager, Aeroflow Breastpumps

Email: carly.fleming@aeroflowinc.com

Share article on social media or email:

PKF O’Connor Davies Hires Tina Wei as Director, Transaction Advisory Services


“Tina has a proven track record of helping clients navigate complex transactions and investments, and we’re thrilled to welcome her to the team,” said Jonathan Moore, Partner-in-Charge, Transaction Advisory Services.

PKF O’Connor Davies, LLP, one of the nation’s largest accounting, tax, and advisory firms, announced today it has hired Tina Wei to serve as Director of Transaction Advisory Services in the Firm’s New York City office. Wei’s expertise and leadership enhances the Firm’s transaction advisory practice and demonstrates its commitment to recruiting top talent. Wei joins the Firm after spending more than 15 years at a Big 4 accounting firm.

“Tina has a proven track record of helping clients navigate complex transactions and investments, and we’re thrilled to welcome her to the team,” said Jonathan Moore, Partner-in-Charge, Transaction Advisory Services. “Yet another hire from a Big 4 accounting firm speaks volumes about the complexity and quality of our work. It shows we’re exceeding our high-caliber clients’ expectations as we expand our national and international presence in the transaction advisory space.”

Prior to joining the Firm, Wei led cross-function M&A teams to consult through more than 100 deals for clients regarding all aspects of transactions, including Quality of Earnings, Quality of Assets, Net Working Capital and Net Debt, SPA review and post-close integration. These domestic and cross-border transactions spanned across various industries with a focus in the telecom, media, technology, retail, and consumer goods sectors.

“In each transaction I support, my focus is on providing the best possible advisory services and insights to the client,” said Wei. “From my first interactions with the transaction advisory team at PKF O’Connor Davies, it was clear they shared that commitment, and I look forward to working together to best serve our clients.”

Wei is a graduate of Nanjing University in China and received her M.B.A. from the University of Michigan. She is a certified public accountant and is a member of the American Institute of Certified Public Accountants.

PKF O’Connor Davies has 12 offices in five states and continues to expand through organic growth and acquisitions on the East Coast. It has supported this growth with a strategic combination of promoting from within coupled with tactical external hires.

About PKF O’Connor Davies, LLP

PKF O’Connor Davies, LLP is a full service certified public accounting and advisory firm with a long history of serving clients both domestically and internationally. With roots tracing to 1891, 12 offices in New York, New Jersey, Connecticut, Maryland and Rhode Island and more than 800 professionals led by over 100 partners, the Firm provides a complete range of accounting, auditing, tax and management advisory services.

PKF O’Connor Davies is a top-ranked firm according to Accounting Today’s 2020 “Top 100 Firms” list and the Firm is also recognized as a “Leader in Audit and Accounting,” a “Pacesetter in Growth” and one of the “Top Firms in the Mid-Atlantic.” In 2021, PKF O’Connor Davies was named one of Vault’s Accounting 50, a ranking of the 50 best accounting employers to work for in North America and ranked among the top 50 most prestigious accounting firms in America in a complementary Vault survey. The Firm is the 12th largest accounting firm in the New York Metropolitan area, according to Crain’s New York Business, and the 10th top accounting firm in New Jersey according to NJBiz’s 2019 rankings.

PKF O’Connor Davies is enrolled in the AICPA Peer Review Program and has central memberships in the Private Companies Practice Section (PCPS), the Employee Benefit Plan Audit Quality Center (EBPAQC), Government Audit Quality Center (GAQC) and Public Company Accounting Oversight Board (PCAOB).

By consistently delivering proactive, thorough and efficient service, PKF O’Connor Davies has built long-lasting, valuable relationships with its clients. Partners are closely involved in the day-to-day management of engagements, ensuring a high degree of client service and cost effectiveness. The Firm’s seasoned professional staff members employ a team approach to all engagements to provide clients with the utmost quality and timely services aimed at helping them succeed. Continuity of staffing and attention to detail in all client engagements make the Firm stand out among its competitors.

PKF O’Connor Davies is the lead North American representative of the international association of PKF member firms. PKF International is a network of legally independent member firms providing accounting, tax, and business advisory services in over 400 locations in 150 countries around the world. With its tradition, experience and focus on the future, PKF O’Connor Davies is ready to help clients meet today’s ever-changing economic conditions and manage the growing complexities of the regulatory environment. For more information, visit http://www.PKFOD.com.

# # #

Share article on social media or email:

Proactive Strategies to Avoid Supply Delays to be Presented by Catalent at Outsourcing in Clinical Trials Virtual Conference


Catalent, a global leader in clinical supply services, today announced that Stephanie Graham, Regional Manager, Clinical Supplies Management, will present at the upcoming conference, ‘Outsourcing in Clinical Trials 2020 – A Virtual Experience’, which takes place on May 27, 2020.

Ms. Graham’s presentation, at 11:30 a.m., titled “Proactive Strategies to Identify Clinical Supply Risks and Avoid Study Delays”, will discuss the types of sponsors and studies which may be at a greater risk of experiencing clinical supply challenges, and will illustrate how sponsors may be able to avoid costly study delays by identifying study characteristics that are most likely to indicate that potential issues lie ahead.

Ms. Graham has more than 13 years of experience in clinical supplies management, packaging and distribution, in addition to 13 years spent working in international shipping. Prior to joining Catalent in 2015, she held roles at Fisher Clinical Services, Shire Pharmaceuticals and Takeda.

For further information, please visit: https://www.clinical.catalent.com/events/outsourcing-in-clinical-trials-2020-a-virtual-experience

About Catalent Clinical Supply Services

Catalent is a global leader in clinical supply services, with comprehensive and flexible solutions for small molecules, biologics, and cell and gene therapies and integrated solutions to accelerate speed to clinic. Catalent offers a full range services including clinical supply management, comprehensive packaging solutions, comparator sourcing, cold chain storage and global distribution and specialized supply chain services including direct-to-patient and demand-led supply. With nine GMP clinical packaging facilities and over 50 strategically located depots on six continents combined with more than 25 years’ experience across thousands of studies in more than 80 countries, Catalent has the comprehensive services, global scale and expertise necessary to reliably supply clinical trials of all sizes and complexity anywhere in the world.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including approximately 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

R&D Quality as the Foundation for Product Quality, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

Even early-stage R&D benefits from a quality mindset and the speaker will discuss ways that the R&D Quality Group supports the programs.

This webinar will focus on current practices in use at Cytovance Biologics as part of product lifecycle management. At times, projects are received with differing amounts of background information and this webinar will discuss control of quality during the various stages of R&D while still maintaining the flexibility necessary for research. There must be dynamic balancing of expectations for quality with the needs of the scientists to understand and characterize the material being produced particularly in R&D.

Even early-stage R&D benefits from a quality mindset and the speaker will discuss ways that the R&D Quality Group supports the programs. Flexibility is key at this stage and R&D quality activities evolve to focus on the needs of the scientists to collect valid data. As the processes and procedures become better established, the amount and types of documentation increase.

R&D Quality activities in the latter phases of research and development are controlled to allow the ultimate assembly of a documentation package to support the clients’ submissions to regulatory bodies. Documentation at this point includes both written procedures used by R&D to produce the material and method transfer reports that support the eventual authoring of scaled up current Good Manufacturing Practice (cGMP) batch records.

The FDA expects that the drug substance used for toxicology and other testing will be representative of the material eventually produced in cGMP Manufacturing. R&D Quality is part of the team reviewing documentation of production and testing. In many cases, clients request GLP testing of the Tox material. Good Laboratory Practices (GLP) testing is a formal prospective test plan administered by R&D Quality and performed by R&D scientists.

Join Gregory Svanas, Director of Research and Development Quality, Cytovance Biologics in a live webinar on Monday, June 1, 2020 at 12pm EDT (5pm BST/UK).

For more information or to register for this event, visit R&D Quality as the Foundation for Product Quality.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com.

For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar/.

Share article on social media or email:

NYC Real Estate Experts Share Intel on Getting Deals Done During a Pandemic


Richard Haggerty, CEO of HGAR and president of OneKey™ MLS

“Our industry is facing myriad challenges posed by the pandemic, but deals are happening – we had 131 new listings submitted in just the last 24 hours,” said Haggerty.

The Hudson Gateway Association of Realtors, Inc. (HGAR) and OneKey™ MLS have teamed up with TitleVest to offer complimentary webinars on real estate transaction best practices to help agents and brokers navigate the changing landscape during the COVID-19 crisis.

Hundreds of industry professionals tuned in April 30 for the launch of “Getting the Deal Done in NYC: Real Estate Transaction Best Practices During a Pandemic,” which was hosted by Richard Haggerty, CEO of HGAR and president of OneKey™ MLS, the new regional multiple listing service for New York.

“Our industry is facing myriad challenges posed by the pandemic, but deals are happening – we had 131 new listings submitted in just the last 24 hours,” said Haggerty. “That’s why we put together this series, to share with our colleagues the latest developments to help get those deals done – safely and efficiently.”

The hour-long session focused on pre-closing strategies for renegotiations, due diligence, title searches and digital-document transfers.

“We’re starting to see more and more contracts being signed and all of this increased activity presents tremendous opportunities,” said Brian D. Tormey, NTP, president of TitleVest, a leading New York City-based provider of title insurance and related real estate services. “We’re here today to explore what we should be doing now to set ourselves up for success as we navigate forward.”

Tormey moderated the in-depth panel discussion, which featured real estate attorney Bruce M. Cohen, founding partner of Cohen and Frankel in New York City, and Jim Brune, founder of BoardPackager, an online platform for real estate transactions that enables qualifying parties to digitally disseminate and receive diligence and process applications, payments and transfers.

“We’re feeling the pulse and we’re going to see more listings coming up. There’s a real opportunity for your clients right now to get into the ballgame,” said Cohen. “Get your due diligence done ahead of time, with pre-approvals and so forth, so you can hit the ground running post- COVID-19.”

In the second part of the series on May 7, Cohen and Brune shared intel on closing real estate transactions, from remote notarizations and appointing a power of attorney, to getting signed contracts and “virtual” vs. “table” closings.

“The pandemic has hastened the move to digital and agents need to leverage that technology,” said Brune. “Once the executive order is lifted, there will be resistance to fully staff building management and other offices. We have these digital platforms in place now to be prepared for what’s next.”

The third part of “Getting the Deal Done” is scheduled for May 14 and will feature a panel of top producers in New York City discussing strategies for conducting deals during the pandemic and preparing for the road to recovery. The series is part of the “Be Your Best” webinar program created by HGAR and OneKey™ MLS, to assist Realtors and agents during the COVID-19 pandemic. To sign up, visit https://us02web.zoom.us/webinar/register/WN_35xWy4BTRGqQh-6DQWLMWg.

About OneKey™ MLS

OneKey™ MLS has 44,000-plus subscribers and serves Manhattan, Westchester, Putnam, Rockland, Sullivan, Orange, Nassau, Suffolk, Queens, Brooklyn, and the Bronx. It was formed in 2018, following the merger of the Hudson Gateway Multiple Listing Service and the Multiple Listing Service of Long Island.

About Hudson Gateway Association of Realtors

The Hudson Gateway Association of Realtors® (http://www.hgar.com) is a not-for-profit trade association representing more than 13,000 real estate professionals in Manhattan, the Bronx, Westchester, Putnam, Rockland and Orange counties. It is the second-largest Realtor association in New York, and one of the largest in the U.S.

About TitleVest

Founded in 2000, TitleVest (http://www.titlevest.com) is a leading New York City-based title insurance agency and member of the First American family of companies, offering a full range of title insurance and related services for real estate property purchase and refinance transactions. TitleVest has earned the New York Law Journal’s “Best Title Agency” award for seven consecutive years. TitleVest has offices in Manhattan and Westchester, and engages in transactions upstate, downstate and throughout the U.S.

Share article on social media or email:

Steven Basta Joins the DermBiont, Inc. Board of Directors


News Image

Having led multiple therapeutics and healthcare organizations as CEO, Steven brings an exceptional track record as an executive to the Board of Directors here at DermBiont, the world’s leading skin microbiome therapeutics company.

DermBiont, a clinical stage microbiome biotechnology company developing topical live biotherapeutics, is pleased to announce that Mr. Steven Basta has been appointed to the company’s board of directors, effective immediately.

“Having led multiple therapeutics and healthcare organizations as CEO, Steven brings an exceptional track record as an executive to the Board of Directors here at DermBiont, the world’s leading skin microbiome therapeutics company. Our entire leadership team is excited to benefit from his experience as we continue to advance our discovery programs and products in development,” said Karl Beutner, CEO of DermBiont.

“DermBiont has built an incredible platform and culture that enables the company to discover and advance microbial therapeutics through the clinic much faster and more efficiently than traditional therapeutics,” said Steven Basta. “I look forward to working with Karl and the leadership team. The entire DermBiont organization is committed to developing novel therapeutics that treat skin diseases at their root cause, a dysbiosis of the cutaneous microbiome.”

Mr. Basta most recently served as the President and CEO of Menlo Therapeutics, a dermatology therapeutics development company. Mr. Basta previously served as CEO at AlterG Inc, BioForm medical (acquired by Merz), Merz Aesthetics, and Gliatech. He currently sits on the board of Menlo Therapeutics, and serves as the Chairman of the Board of Viveve Medical.

DermBiont’s other current board members are: Karl Beutner, CEO, DermBiont (formerly CMO of Anacor, sold to Pfizer for $5.2B in 2016); Wilder Ramsey, Partner, Toba Capital; Nichola Eliovits, Managing Partner, Olive Tree Capital.

About DermBiont

DermBiont is the world’s leading dermatology company leveraging skin microbiome therapeutics (live biotherapeutics) to treat the root cause of skin diseases. In addition to the company’s lead product in development to treat Onychomycosis and Atopic Dermatitis, DBI-001, the company is advancing four other clinical assets across a wide range of skin diseases caused by a dysbiosis of the microbiome. The company’s discovery capabilities are powered by a proprietary computational biology platform enabling the rapid discovery of hits against pathogens from a curated library of thousands of microbes isolated from human skin and one of the world’s largest data sets of Nextgen sequencing of the human microbiome across healthy and diseased skin.

Send all inquiries to: press@dermbiont.com

http://www.dermbiont.com

Share article on social media or email:

Thought Technology’s Webinar Series Aims to Educate Health Professionals on the Benefits of sEMG Biofeedback


biofeedback, sEMG, electromyography,

sEMG biofeedback is highly motivating for both children and adults and the powerful engagement created, sets the stage for new movement habits and positive neuroplastic changes.

In an upcoming live webinar, Pia Stampe, PT, DPT will discuss sEMG Biofeedback as an effective intervention tool in neuro-rehabilitation. sEMG Biofeedback is an under-utilized intervention for pediatric and adult patients with neurological impairments. Dr. Stampe will show the immediate effect of using biofeedback to create awareness and efficient muscle recruitment/relaxation and how this results in rapid functional improvements. sEMG Biofeedback is highly motivating for both children and adults and the powerful engagement created, sets the stage for new movement habits and positive neuroplastic changes. This webinar will dispel the common perception of sEMG Biofeedback being complicated and difficult to use as a rehabilitation tool.

sEMG Biofeedback in NeuroRehabilitation: The power of the “a-ha” moments

Presenter: Pia Stampe, PT, DPT

Date: May 20, 2020

Time: 1:00-2:00 pm EDT

Click here to register.

About Pia Stampe, PT

Pia Stampe (PT, DPT), is the owner and founder of KeytoCP Intensives, formerly Step by Step CP Intensives. Pia is a pediatric physical therapist with more than 35 years of experience working with children with cerebral palsy. She graduated from PT education in Copenhagen, Denmark in 1981 and earned her Doctor of Physical Therapy degree from AT Still University in 2008. Pia has completed extensive continuing education and has teaching experience in pediatrics/neurology, coaching and use of EMG biofeedback, neuromuscular stimulation, and functional electrical stimulation. Pia has worked closely with Karen Pape, MD as the systematic, intensive model used at KeytoCP was developed.

About Thought Technology Ltd.

Founded in 1975, Thought Technology is the world’s leading biofeedback and physiological instrument manufacturer. Its products are used as an essential part of many therapeutic treatments and clinical assessment protocols in over 85 countries and are used by tens of thousands of clinicians in thousands of medical institutions.

Always supportive of new research and development ideas, Thought Technology Ltd. has encouraged a number of special interest groups and clinicians to create cutting edge applications for its instrumentation. Thought Technology Ltd. equipment is now being used in telemedicine, web-based monitoring and biofeedback, sports training, research in human-machine interface, physiology-driven multimedia environments and virtual reality. Constantly striving to improve the quality of the products and services, TTL has obtained, and maintains, ISO 13485, and CE certification for the organization and products.

Share article on social media or email:

Clear Labs Raises $18M; Plans to Expand Application of Automated Next-Generation Sequencing Platform to COVID-19 Diagnostics


News Image

Clear Labs’ fully- automated NGS platform with its flexible and robust architecture has allowed the company to develop a turn-key genomics-based assay that hasn’t before existed in the clinical space and will provide a new layer of COVID-19 testing never before possible.

Clear Labs, providers of the only automated and intelligent diagnostic NGS platform, today announced the raise of a $18M strategic round of funding led by Redmile Group, as well as existing investors including Wing VC, Menlo Ventures, Tyson Ventures, Khosla Ventures, GV, Felicis Ventures, and HBM Genomics. To date, Clear Labs has raised $62M.

In addition to supporting ongoing commercialization of the company’s food safety platform, Clear Safety, the funds will be used to leverage the company’s underlying Next Generation Sequencing (NGS) technology in the clinical market, specifically to enhance the availability and quality of COVID-19 diagnostic tests.

Experts agree that the limitations of COVID-19 testing have been a large contributing factor to the spread of the virus in the United States. Aside from an initial shortage of tests, the existing gold standard diagnostic screening shows 10-30% false negative rates. With such a high rate of false negatives, the other concern is when a symptomatic patient has a negative test result. Symptoms of COVID-19 are often similar in nature to the common cold or flu, making it difficult to decipher if a test result is a false or true negative. Additionally, testing for asymptomatic patients is nearly nonexistent, preventing officials from fully understanding how the virus has spread.

While the lack of ability to track infection clusters and transmission routes presents serious challenges, current mainstream diagnostic tests (including qPCR, and LAMP) are also unable to follow emerging mutations that could create different versions of the virus in the future. This could lead to problematic resistance against new and emerging pharmaceutical interventions intended to target COVID-19.

Clear Labs’ fully- automated NGS platform with its flexible and robust architecture has allowed the company to develop a turn-key genomics-based assay that hasn’t before existed in the clinical space and will provide a new layer of COVID-19 testing never before possible.

“We saw an important opportunity to help stop the global spread of COVID-19 with the platform we’ve developed over the last 6 years. Our technology, while built originally for food safety, has become a powerful genomic tool with unmatched cost, time-to-results, and ease of use that can provide great benefit to the clinical market,” said Sasan Amini “Our genomics-based assay not only provides significantly higher rates of accuracy for detection of SARS-CoV-2, it prepares us for the future of the virus. Clear Labs’ technology will be able to keep up with the rapid evolution of viral RNA so that labs, hospitals and even companies developing therapeutics have up-to-date molecular data to power intervention and large-scale epidemiology.”

Clear Labs’ novel characterizing diagnostic provides hospitals and clinical diagnostic labs with:

Superior Diagnostic

  • Accuracy – effectively eliminates false positives and significantly minimizes false negatives
  • Automation – improves reproducibility, reduces human labor and potential for error – all while providing the highest possible biosafety for operators
  • Cost Savings – Clear Labs’ platform is the most cost-effective sequencing solution available on the market, and enables the highest reimbursement rates
  • Turnaround Time – end-to-end sample to answer is 8 hours
  • Advanced Bioinformatics – provides automated, cloud-based, scalable computational power with no bioinformaticians required


Powerful Genomic Surveillance

  • Non-binary Results – our surveillance tool allows labs to differentiate RNA viruses
  • Drive Intervention – monitor evolution of viral genes that are therapeutic targets
  • Empower Large-Scale Epidemiology – identify infection clusters and transmission routes
  • Recognize Co-Infections – identify cases of co-infection
  • No Additional Cost & Time – all genomic surveillance features are included with screening


“Clear Labs previously developed the first and only high quality, rapid and automated pathogen sequencing system, now in regulated commercial use for food safety testing. Based on feedback from leading experts, Clear Labs rapidly developed a SARS-CoV-2 testing system to address the tremendous global need,” said Greg Yap, Partner at Menlo Ventures. “Clear Labs next-gen sequencing, sample-to-answer system has the potential to improve SARS-CoV-2 testing accuracy and availability worldwide”.

Clear Labs’ platform leverages the latest technology in molecular testing, proprietary bioinformatics software, and robotics. It also includes an unprecedented level of automation and robotics to reduce human labor and errors. Clear Labs’ AI and machine learning provide additional insights and trends, allowing researchers, epidemiologists and clinical labs to track infection clusters, drive intervention, and monitor the evolution of viral genes that are therapeutic targets.

“Our team has been working diligently and tirelessly to deploy our technology to help with COVID-19,” said Ramin Khaksar, VP of R&D. “We hope that the power of our platform and what we’ve built will help us all better understand and act on this virus. We’re grateful to everyone who has been on the front lines, and we’re honored to do our part to help.”

Clear Labs is already working with leading hospitals, universities, and labs on deploying the test and expect to receive the FDA Emergency Use Authorization (EUA) within the coming days.

To learn more about Clear Labs and to pre-register for its novel characterizing diagnostic, please visit: http://www.clearlabs.com/covid-19.

About Clear Labs

Clear Labs is the only automated and intelligent diagnostic NGS platform. We help our customers capitalize on a new era of technology by seamlessly integrating DNA sequencing, bioinformatics, and robotics. The result democratizes genomics within settings never before possible.

With these capabilities, Clear Labs has become a prominent and credible platform for safeguarding the global food supply and enhancing preventative food safety management systems. Now, we are leveraging our novel genomics platform for deep COVID-19 characterizing diagnostics.

The world’s largest brands and organizations have implemented and are already realizing the advantages of the Clear Labs’ system.

To learn more, please visit: http://www.clearlabs.com/.

Share article on social media or email:

AsSeenOnTV.pro and Kevin Harrington’s DRTV Campaign with the CuraLin by CuraLife


Millions of Americans have diabetes. According to the CDC, 90 to 95 percent of Americans with diabetes have type 2. The disease can be fatal if left untreated, but the lifestyle constraints of traditional pharmaceuticals can be so awful that people don’t want to deal with them. This is why CuraLife created CuraLin — an all-natural glucose support supplement, that helps ease lifestyle constraints so that diabetics can truly enjoy their lives again.

CuraLin is a one hundred percent natural supplement that promotes healthy glucose levels, energy, sleep, and proper body function. Using a synergetic formula, CuraLin targets key areas of system health on many levels important for people with diabetes. Tens of thousands of customers look to CuraLin for effective glucose support. It helps their body maintain optimal performance as other bodies do.

“By helping those with type 2 diabetes keep their blood sugar in the healthy range, CuraLin helps them enjoy a healthy, normal life,” says Ron Elul, CEO of CuraLife. “Diabetes is about more than blood sugar. It can make people feel out of place if they can’t join their friends out for dinner or don’t have the energy to spend time with their family. Everyone knows someone who’s diabetic. We’re happy to be sharing our all-natural supplement with as many people as possible, thanks to working with AsSeenOnTV.pro.”

“CuraLin is phenomenal,” says Lisa Vrancken, Executive Vice President of Business Development at AsSeenOnTV.pro. “It allows people with type 2 diabetes to enjoy a naughty treat here and there, instead of being envious of those who can. CuraLin helps them get back their quality of life.”

As part of its DRTV campaign with AsSeenOnTV.pro, CuraLin will be appearing in 30 second spots set to air nationwide and feature the original Shark himself, Kevin Harrington. AsSeenOnTV.pro is comprised of an award-winning team of producers, writers, videographers, and editors as well as industry veterans dedicated to finding the latest, most innovative products and ideas, and putting them on the DRTV map.

About AsSeenOnTV.pro

Headquartered in South Florida, AsSeenOnTV.pro is a full-service production, branding, and marketing company that specializes in direct response television, short- and long-form commercials, and brand building. Based out of a 25,000+ sq ft, state-of-the-art studio, the company’s creative team handles every aspect of production from script to screen to airing. For nearly two decades, AsSeenOnTV.pro’s veteran staff of writers, producers, videographers, and editors has amassed more than 50 Telly Awards, thousands of prestigious clients, and over $20 million in television placements.

About Kevin Harrington

As the inventor of the infomercial, founder of As Seen on TV, and one of the original Sharks on Shark Tank, Kevin Harrington has worked with some of the world’s biggest celebrities and launched some of the best-selling DRTV campaigns in history. Since producing his first 30-minute infomercial in 1984, Harrington has been involved in over 500 product launches that have resulted in over $4 billion in sales. Now, in his latest venture with AsSeenOnTV.pro, Harrington is on the hunt for the best new products and ideas, bringing them to homes everywhere through personalized DRTV campaigns featuring the Shark.

For more information on CuraLin, please visit http://www.curalife.com.

Share article on social media or email:

T1 Payments Donates to Nevada Community Foundation to Assist Frontline Workers During COVID-19 Pandemic


T1 Payments Nevada Community Foundation

T1 Payments Donates to Nevada Community Foundation to Assist Frontline Workers

“With our donation, we hope to keep our frontline workers safe so they can return home to their families every day,” said a T1 Payments representative. “We need to do our best to support and protect all frontline workers from the COVID-19 pandemic.”

T1 Payments, a leader in high-risk merchant processing, is donating to the Nevada Community Foundation’s COVID-19 Emergency Response Fund in an effort to assist with the State’s response, relief, and recovery efforts during the Coronavirus (COVID-19) pandemic.

Nevada Community Foundation and Nevada COVID-19 Response, Relief, and Recovery Task Force are partnering to support the state of Nevada, distributing supplies to the areas of greatest need. The fund focuses on providing first responders and healthcare providers with personal protective equipment (PPE), ventilators, testing supplies, and other medical supplies.

T1 Payments’ contribution will assist Nevada’s medical community and first responders, providing critical resources needed to keep health care workers and other frontline workers protected. This will help reduce pressure on medical capacity, supporting the most essential members and true heroes in the community.

“With our donation, we hope to keep our frontline workers safe so they can return home to their families every day,” said a T1 Payments representative. “We need to do our best to support and protect all frontline workers from the COVID-19 pandemic.”

T1 Payments is proud to give back to the medical community during this time of uncertainty. With their ongoing donations and support, T1 Payments hopes Nevada recovers soon from the COVID-19 pandemic.

T1 Payments continues to increase awareness and fund programs in effort to bring everyone in the Nevada community together.

For more information about how to donate to help frontline workers impacted by the COVID-19 pandemic, visit the Nevada Community Foundation website.

More about T1 Payments:

T1 Payments is a high-risk merchant processing company that is flexible, transparent, and scalable. T1 Payments’ secure gateway and integrated shopping cart solutions are compliant with all Payment Card Industry Data Security Standards (PCI DSS).

In addition to high-risk merchant processing services, T1 Payments stays involved in the community through its ongoing donations and sponsorships. To learn more about the nonprofits T1 Payments supports, visit T1 Payments Community Involvement page on their website.

For more information, please visit the T1 Payments website (https://t1payments.com/) or call 1-866-518-2216.

Share article on social media or email: